PVLA
Palvella Therapeutics Achieves Landmark Year, Sets Stage for FDA Approval and Commercialization of Rare Disease Therapies
Palvella Therapeutics has marked a significant milestone in its journey towards becoming the leading rare disease biopharmaceutical company. In a recent conference call to discuss its full year 2025 financial results, the company highlighted several value-creating milestones achieved during the year. One of the most notable achievements was the announcement